Research scientist Safia Guleed, PhD will share our progress within in vivo CAR therapy. This includes our first-in-class T-cell depleting in vivo CAR-M that is being developed for T cell-dependent inflammatory diseases like refractory asthma, psoriatic arthritis, ICI colitis, and myositis with ILD. The presentation also includes novel data on our LNP-conjugation platform that demonstrates greatly increased potency compared to benchmarks, thus providing potential to reduce cost of goods for any tLNP-based therapy.